Pharmicell Co., Ltd. (KOSE:A005690) announced a private placement of first unregistered unsecured private convertible bonds for gross proceeds of KRW 8,000,000,0000 on April 4, 2014. The transaction will include participation from new investor, KDBC Bio Medical New Growth Potential Investment Fund, business execution union member of KDB Capital Corporation, Future Creation Neoplux Investments Fund, business execution union member of Neoplux Co., Ltd., KoFC-Neoplux R&D-Biz Creation 2013-1 Investment Fund, business execution union member of Neoplux Co., Ltd., and Wings Partner Co. Ltd., which will invest KRW 2,000,000,000, KRW 1,500,000,000, KRW 1,500,000,000, and KRW 3,000,000,000, respectively in the transaction.

The bonds will have an annual coupon of 3% and yield to maturity of 7%. The bonds will mature on April 7, 2018. The bonds will be convertible into common shares at KRW 3,979 per share and conversion period will be from April 7, 2015 to March 7, 2018.

The payment date is April 7, 2014. The transaction was approved by board of directors of the company.